Shares of VistaGen Therapeutics Inc VTGN 56.95% rocketed up over 40 percent to $1.36 in after-hours trading on Thursday — a mere fraction of the 500 percent upside implied by a late-day note from Oppenheimer. Oppenheimer’s Jay Olson initiated coverage on VistaGen with an Outperform rating and $6 price target. SourceSome consolidation is possible. However, it's better to wait for more clear signals. We can probably expect a downside with gap-closing in the nearest time. $VTGN, VistaGen Therapeutics, Inc. / D